This inventor holds 2 USPTO granted patents and 2 published patent applications and 1 EPO patent. Top assignees: Idenix Pharmaceuticals, Inc., Centre National De La Recherche Scientifique, Universitè De Montpellier. Active years: 2012-2019.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
2 out of 100 
1 out of 5,383 
1 out of 298 
Years Active: 2012-2019
Title: The Innovations of Jean-Francois Griffon
Introduction
Jean-Francois Griffon is a notable inventor based in Teyran, France. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of viral infections. With a total of two patents to his name, Griffon's work focuses on innovative compounds that target HCV infections.
Latest Patents
Griffon's latest patents include the development of 2'-chloro nucleoside analogs for HCV infection. These compounds, compositions, and methods are designed for the treatment of Flaviviridae infections, including HCV. The patents disclose nucleoside derivatives that can be administered alone or in combination with other antiviral agents. Additionally, he has developed phosphothiophene and phosphothiazole HCV polymerase inhibitors. These compounds are aimed at providing effective treatment options for hosts infected with HCV.
Career Highlights
Throughout his career, Jean-Francois Griffon has worked with prominent organizations such as Idenix Pharmaceuticals, Inc. and the Centre National De La Recherche Scientifique. His experience in these institutions has allowed him to advance his research and contribute to the development of innovative treatments for viral infections.
Collaborations
Griffon has collaborated with notable colleagues, including Cyril B Dousson and Claire Pierra. These partnerships have played a crucial role in enhancing his research and expanding the impact of his inventions.
Conclusion
Jean-Francois Griffon's contributions to the field of pharmaceuticals, particularly in the treatment of HCV infections, highlight his innovative spirit and dedication to advancing medical science. His patents reflect a commitment to developing effective antiviral therapies that can significantly improve patient outcomes.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile